Search

Your research
 

15 documents found for "NCE"

1. Cancer

AF122 : anti-cancer drug against Acute Myelogenous Leukemia. Leukemia grows up in bone marrow and is characterized by an abnormal and excessive proliferation of white blood cell-precursors, blocked at a stage of differentiation, which finally invade the entire bone marrow and cause medullary insufficiency with insufficient production of red blood cells, and white blood cells, mainly polynuclear ones, and platelets. The ...

2. NCE

The proprietary molecules of Affichem are natural New Chemical Entities (NCE) discovered while studying the mechanism of action of Tamoxifen in INSERM lab of Dr Marc POIROT. These molecules are strong inducers of cell differentiation.   Due to their effects, these molecules enable damaged cells or cells perturbed by a disease, a trauma or age, either to recover a normal activity or to ...

3. Affichem USA Inc.

Affichem creates a subsidiary in the USA in the State of New Jersey: Affichem USA Inc. In November 2013, the management of Affichem formed a U.S. subsidiary to cultivate ties with the USA and other major pharmaceutical markets. It is essential for the French biotechnology company to have an international presence in order to successfully develop and commercialize its technology. The publication ...

4. Predictive & Monitoring Biomarker

Biomarker AF300. Affichem is developing a biomarker to improve the care of breast cancer. Breast cancer is the most widespread cancer in women, representing 1.4M new cases per year and death. Breast cancers are stratified, and treatment is chosen, mainly on the basis of three markers, roughly discriminating 4 sub-types of breast cancers. To date, the overall 5-year survival rate is over 80% in ...

  • Home
  • > R&D
  • > Predictive & Monitoring Biomarker

5. Links

http://www.inserm.fr/ http://www.claudiusregaud.fr/ http://www.eurohear.org/ http://cordis.europa.eu/fp6/dc/index.cfm?fuseaction=UserSite.FP6HomePage http://www.inserm-transfert.fr/ http://www.oseo.fr/ http://www.cancerbiosante.fr/ http://www.incubateurmipy.com/ http://www.midipyrenees.fr/ http://www.enseignementsup-recherche.gouv.fr/ http://www.grandtoulouse.org/ http://www.sigmaaldrich.com/ http://www.spibio.com/ ...

6. Legal notice

Legal notice This page describes the legal mentions which apply to any user visiting this site. By consulting it, the user agrees without reserve to respect them. The legal mentions being able to be modified constantly and without notice, we urge the user to consult them regularly. 1/ PROPERTY This website (hereafter “the Site”) is owned and published by : ...

7. Investors

Up until now, Affichem is 100% owned by physical persons. Co-founders were joined by business angels and crowdfunding investors. About half of expenses have been financed by non dilutive resources (collaborative R&D programs, public funds). In 2015, technological maturity of Affichem products allows the company to initiate a global fund-raising program and study partnership opportunities. For more information : info@affichem.com ...

8. Publications

de Medina P., Payré B., Bernad J., Bosser I., Pipy B., Silvente-Poirot S., Favre G., Faye J. C., and Poirot M. Tamoxifen is a Potent Inhibitor of Cholesterol Esterification and Prevents the Formation of Foam Cells. J Pharmacol Exp Ther, 308: 1165-1173, 2004. Kedjouar B., de Medina P., Oulad-Zegarry M., Payre B., Silvente-Poirot S., Favre G., Faye J. C., and Poirot,M. ...

9. Hearing loss

AF243 : a drug to restore hearing. The World Health Organization estimated in 2005 that 278 million people in the world suffered from a severe or moderate bilateral auditory deficiency, that is 4.2% of the world population, and shall raise 500 million by 2025. Only 25% of the people concerned are equipped with hearing aids in the developed countries. The unmet medical need ...

10. Biomarkers

Discovery of a biomarker for cancer detection and monitoring the efficacy of anti-cancer drugs : AF300.  As a result of metabolomic research in oncology, a new metabolite, named AF300, has been identified that is accumulated in various tumors and involved in tumor progression and invasiveness. A patent related to its properties and identification was granted in June 2011. All the steps leading ...

Results pages

12>
 
Biomarker - Drug design - Anticancer therapy - Cell differentiation - Receptor - Enzyme - Metabolism - Cancer - Deafness - Melanoma - Neurodegenerative disease - Medicinal chemistry - Biotechnology - First in class molecule - New Chemical Entities - Cholesterol - Tamoxifen - Immunotherapy - Exosome - Oncology - Dendritic cell - Theranostic - Diagnosis - Prognosis -